ReviewFrontiers in nutrition2026
Chrononutritional regulation of metabolic homeostasis: intermittent fasting through gut microbiota, circadian rhythms, and autophagy.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global obesity epidemic has increased the burden of metabolic diseases. Dietary interventions are key to managing obesity and improving metabolic health. Intermittent fasting (IF) has emerged as a promising chrononutritional intervention that may modulate metabolic metabolic homeostasis through timed eating-fasting cycles. This review examines four main IF patterns:time-restricted feeding (TRF), alternate day fasting (ADF), the 5:2 fasting, and the 4:3 fasting, and evaluates their effects on body weight, glucose homeostasis, insulin sensitivity, and lipid profiles. Furthermore, it delineates the mechanistic pathways through which IF confers metabolic benefits beyond caloric restriction alone: (1) alleviating insulin resistance by enhancing the intestinal mucosal barrier and upregulating GLP-1 expression suppressing endotoxemia-related inflammation; (2) restoring circadian rhythmicity in the expression of metabolism-related genes to correct metabolic dysregulation; (3) increasing energy expenditure and lipid oxidation via short-chain fatty acid-mediated browning of white adipose tissue (WAT); and (4) enhancing cellular autophagy through activation of the SIRT3-AMPK-mTOR signaling pathway, thereby improving overall metabolic function. Evidence supports IF as a potentially effective alternative for obesity and metabolic disorders through chronobiological mechanisms. However, potential adverse effects like hypoglycemia and adherence challenges highlight the need for individualized approaches in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.